UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Takeda to Present Data During 60th American Society of Hematology Annual Meeting on Wide Array of Treatment Needs for Blood Cancers

Business Wire, 2018-11-01

2018

Link zum Volltext

Verfügbarkeit prüfen

European Commission Approves Expanded Indication for Merck's KEYTRUDA[R]

Business Wire, 2021-03-17

2021

Link zum Volltext

Verfügbarkeit prüfen

European Commission Approves Expanded Indication for Merck's KEYTRUDA (pembrolizumab) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

Business Wire, 2021-03-17

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase 3 SHINE Results Show IMBRUVICA (ibrutinib)-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly Diagnosed Mantle Cell Lymphoma

PR newswire, 2022-06-03

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase III FIRST (lenalidomide) Plus Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplant Published in New England Journal of Medicine

Business Wire, 2014-09-04

2014

Link zum Volltext

Verfügbarkeit prüfen

Sprycel (dasatinib) Added to Standard Chemotherapy Demonstrates Three-Year Survival Benefit in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Business Wire, 2017-12-09

2017

Link zum Volltext

Verfügbarkeit prüfen

Initial Phase III Results of the FIRST Trial (MM-020/IFM 07 01) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (PTS) Ineligible for Stem Cell Transplantation (SCT) Accepted for Plenary Presentation at ASH Annual Meeting

Business Wire, 2013-11-07

2013

Link zum Volltext

Verfügbarkeit prüfen

Initial Phase III Results of the FIRST[R] Trial Accepted for Plenary Presentation at ASH Annual Meeting

Business Wire, 2013-11-07

2013

Link zum Volltext

Verfügbarkeit prüfen

FDA Expands Indication for REVLIMID[R]

Business Wire, 2017-02-22

2017

Link zum Volltext

Verfügbarkeit prüfen

FDA Expands Indication for REVLIMID (lenalidomide) as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Hematopoietic Stem Cell Transplant (auto-HSCT)

Business Wire, 2017-02-22

2017

Link zum Volltext

Verfügbarkeit prüfen

Pooled Data from Meta-Analysis Suggest Significant Overall Survival Benefit of Investigational REVLIMID Maintenance Following Autologous Stem Cell Transplant in Multiple Myeloma

Business Wire, 2016-06-03

2016

Link zum Volltext

Verfügbarkeit prüfen

European Medicines Agency's CHMP Recommends Approval of Merck's KEYTRUDA (pembrolizumab) for the Treatment of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Business Wire, 2017-03-24

2017

Link zum Volltext

Verfügbarkeit prüfen

U.S. FDA Approves IMBRUVICA After Failure of One or More Lines of Systemic Therapy

PR newswire, 2017-08-02

2017

Link zum Volltext

Verfügbarkeit prüfen

U.S. FDA Approves IMBRUVICA (ibrutinib) as First and Only Approved Treatment for Adult Patients with Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy

PR newswire, 2017-08-02

2017

Link zum Volltext

Verfügbarkeit prüfen

Updated KEYTRUDA (pembrolizumab) Findings in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma Presented at 58th Annual Meeting of the American Society of Hematology

Business Wire, 2016-12-05

2016

Link zum Volltext

Verfügbarkeit prüfen

AbbVie Announces Ibrutinib Accepted for Review by U.S. FDA

PR newswire, 2017-04-04

2017

Link zum Volltext

Verfügbarkeit prüfen

AbbVie Announces Ibrutinib (IMBRUVICA) Supplemental New Drug Application for Previously Treated Chronic Graft-Versus-Host-Disease (cGVHD) Accepted for Review by U.S. FDA

PR newswire, 2017-04-04

2017

Link zum Volltext

Verfügbarkeit prüfen

Late-Breaking Ibrutinib (IMBRUVICA) Data Show Complete or Partial Response in Two-Thirds of Patients with Chronic Graft-Versus-Host-Disease, a Frequent and Potentially Life-Threatening Complication of Stem Cell Transplant

PR newswire, 2016-12-06

2016

Link zum Volltext

Verfügbarkeit prüfen

U.S. FDA Accepts for Review the Application of Ibrutinib After Failure of One or More Lines of Systemic Therapy

PR newswire, 2017-04-04

2017

Link zum Volltext

Verfügbarkeit prüfen

U.S. FDA Accepts for Review the Application of Ibrutinib (IMBRUVICA) for Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy

PR newswire, 2017-04-04

2017

Link zum Volltext

Verfügbarkeit prüfen

Late-breaking Phase 2 Ibrutinib Study in Chronic Graft-Versus-Host-Disease (cGVHD) Showed Complete or Partial Response in Up to Two-Thirds of Steroid Dependent or Refractory Patients

PR newswire, 2016-12-06

2016

Link zum Volltext

Verfügbarkeit prüfen

Notch Therapeutics Enhances Cell Therapy Expertise with Updates to Scientific Advisory Board

PR newswire, 2022-11-08

2022

Link zum Volltext

Verfügbarkeit prüfen

IMBRUVICA (ibrutinib) Treatment Shows Efficacy and Tolerability in Heavily Treated Chronic Lymphocytic Leukemia Patients Following Allogeneic Stem Cell Transplant

PR newswire, 2015-02-17

2015

Link zum Volltext

Verfügbarkeit prüfen

Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled Melphalan

Business Wire, 2013-03-14

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 24 von 24

Suche als RSS-Feed

Aktive Filter

ThemaStem Cells

PublikationsformZeitungsartikel

Suchergebnisse filtern

Filter anzeigen

Sprache

Englisch
(24)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Kollektion

Nexis Uni
(24)
Factiva
(11)

Zeitschrift / Serie

Business Wire
(13)
Pr Newswire
(11)

Menü

Weitere Dienste

Einstellungen

Takeda to Present Data During 60th American Society of Hematology Annual Meeting on Wide Array of Treatment Needs for Blood Cancers

European Commission Approves Expanded Indication for Merck's KEYTRUDA[R]

European Commission Approves Expanded Indication for Merck's KEYTRUDA (pembrolizumab) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

Phase 3 SHINE Results Show IMBRUVICA (ibrutinib)-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly Diagnosed Mantle Cell Lymphoma

Phase III FIRST (lenalidomide) Plus Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplant Published in New England Journal of Medicine

Sprycel (dasatinib) Added to Standard Chemotherapy Demonstrates Three-Year Survival Benefit in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Initial Phase III Results of the FIRST Trial (MM-020/IFM 07 01) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (PTS) Ineligible for Stem Cell Transplantation (SCT) Accepted for Plenary Presentation at ASH Annual Meeting

Initial Phase III Results of the FIRST[R] Trial Accepted for Plenary Presentation at ASH Annual Meeting

FDA Expands Indication for REVLIMID[R]

FDA Expands Indication for REVLIMID (lenalidomide) as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Hematopoietic Stem Cell Transplant (auto-HSCT)

Pooled Data from Meta-Analysis Suggest Significant Overall Survival Benefit of Investigational REVLIMID Maintenance Following Autologous Stem Cell Transplant in Multiple Myeloma

European Medicines Agency's CHMP Recommends Approval of Merck's KEYTRUDA (pembrolizumab) for the Treatment of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

U.S. FDA Approves IMBRUVICA After Failure of One or More Lines of Systemic Therapy

U.S. FDA Approves IMBRUVICA (ibrutinib) as First and Only Approved Treatment for Adult Patients with Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy

Updated KEYTRUDA (pembrolizumab) Findings in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma Presented at 58th Annual Meeting of the American Society of Hematology

AbbVie Announces Ibrutinib Accepted for Review by U.S. FDA

AbbVie Announces Ibrutinib (IMBRUVICA) Supplemental New Drug Application for Previously Treated Chronic Graft-Versus-Host-Disease (cGVHD) Accepted for Review by U.S. FDA

Late-Breaking Ibrutinib (IMBRUVICA) Data Show Complete or Partial Response in Two-Thirds of Patients with Chronic Graft-Versus-Host-Disease, a Frequent and Potentially Life-Threatening Complication of Stem Cell Transplant

U.S. FDA Accepts for Review the Application of Ibrutinib After Failure of One or More Lines of Systemic Therapy

U.S. FDA Accepts for Review the Application of Ibrutinib (IMBRUVICA) for Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy

Late-breaking Phase 2 Ibrutinib Study in Chronic Graft-Versus-Host-Disease (cGVHD) Showed Complete or Partial Response in Up to Two-Thirds of Steroid Dependent or Refractory Patients

Notch Therapeutics Enhances Cell Therapy Expertise with Updates to Scientific Advisory Board

IMBRUVICA (ibrutinib) Treatment Shows Efficacy and Tolerability in Heavily Treated Chronic Lymphocytic Leukemia Patients Following Allogeneic Stem Cell Transplant

Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled Melphalan

Aktive Filter

Suchergebnisse filtern